Stockreport

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD [Yahoo! Finance]

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unpr [Read more]